IDEAYA Biosciences, Inc. reported $234M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $234M (to Q2 2026). Net income: −$175M, trailing twelve months to Q2 2026. Free cash flow: −$114M, trailing twelve months to Q2 2026. Operating margin: −963%, trailing twelve months to Q2 2026.

IDYAIDEAYA Biosciences, Inc.

Healthcare

$36.12+40% 1Y

$36.12

$25.6752 weeks$42.48

IDYA as reported

IDEAYA Biosciences, Inc. reported $234M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.

$234M

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$175M
Net income · −47% year on year · trailing twelve months to Q2 2026
Free cash flow: −$114M
Free cash flow · −62% year on year · trailing twelve months to Q2 2026
Operating margin: −963%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IDYA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$234M	n/a	Q2 2026
Net income	−$175M	−47%	Q2 2026
EPS	−$1.94	−50%	Q2 2026
Operating margin	−963%	n/a	Q2 2026
Net margin	−870%	n/a	Q2 2026
ROE	−14%	n/a	Q2 2026
ROA	−13%	n/a	Q2 2026
Free cash flow	−$114M	−62%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.